Compare Becton Dickinson and Co (BDX) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Wendys Co — how do they compare? Becton Dickinson and Co trades at $155.79 (market cap $41.51B), while Wendys Co trades at $7.52 (market cap $1.41B). The key difference: Becton Dickinson and Co is far larger — about 29.4× Wendys Co's market cap, and Wendys Co pays the higher dividend (7.55%). Which is the better fit depends on your goals.
| BDX | WEN | |
|---|---|---|
Market Cap | $41.51B | $1.41B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.39 | $11.33 |
52-Week Low | $135.49 | $6.17 |
Enterprise Value | $57.97B | $5.23B |
Dividend Yield | 2.79% | 7.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Wendy's (WEN) trades at $7.50, down 0.66% on the day, with a bullish technical signal and recent meme-driven momentum. The stock shows strong valuation metrics with a P/E of 9.74 and P/S of 0.65, but faces declining net income margins, falling to 7.58% in 2025. Recent earnings beats and a 7.1% dividend yield attract income investors, while Project Fresh initiatives aim to counter traffic and cost pressures.
Outlook remains mixed: low valuation and retail enthusiasm offer upside, but margin compression and high debt pose risks. Analyst consensus is cautious with a $7.96 price target, suggesting limited near-term growth. Key catalysts include Q2 2026 results on August 7 and international expansion progress, though competitive and inflationary headwinds persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
